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P

atients with chronic lymphocytic leukemia or small lymphocytic lymphoma whose tumors carry deletion of chromosome 17p13.1 [del(17p)]
have an unfavorable prognosis and respond poorly to standard
chemoimmunotherapy. Zanubrutinib is a selective next-generation Bruton
tyrosine kinase inhibitor. We evaluated the safety and efficacy of zanubrutinib 160 mg twice daily in treatment-naïve patients with del(17p) disease
enrolled in a dedicated, nonrandomized cohort (Arm C) of the phase III
SEQUOIA trial. A total of 109 patients (median age, 70 years; range, 42–86)
with centrally confirmed del(17p) were enrolled and treated. After a median
of 18.2 months (range, 5.0–26.3), seven patients had discontinued study treatment due to progressive disease, four due to an adverse event, and one due to
withdrawal of consent. The overall response rate was 94.5% with 3.7% of
patients achieving complete response with or without incomplete hematologic recovery. The estimated 18-month progression-free survival rate was
88.6% (95% CI: 79.0–94.0) and the estimated 18-month overall survival rate
was 95.1% (95% CI: 88.4–98.0). Most common all-grade adverse events
included contusion (20.2%), upper respiratory tract infection (19.3%), neutropenia/neutrophil count decreased (17.4%), and diarrhea (16.5%). Grade ≥
3 adverse events were reported in 53 patients (48.6%), most commonly neutropenia (12.9%) and pneumonia (3.7%). An adverse event of atrial fibrillation
was reported in three patients (2.8%). Zanubrutinib was active and well tolerated in this large, prospectively enrolled treatment cohort of previously
untreated patients with del(17p) chronic lymphocytic leukemia/small lymphocytic lymphoma. This trial was registered as clinicaltrials.gov Identifier:
NCT03336333.
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Introduction
Patients with chronic lymphocytic leukemia (CLL) or
small lymphocytic lymphoma (SLL) have historically been
treated with combination chemotherapy and
immunotherapy with success; however, many patients do
not have sustained responses in part due to genomic aberrations that impair responsiveness to therapy. One aberration found in patients with CLL/SLL is the deletion of
chromosome 17p13.1 [del(17p)]; these patients have an
unfavorable prognosis and respond poorly to standard
chemoimmunotherapy, with reduced rates of overall survival (OS) and worse clinical outcomes.1,2 del(17p) results
in the mono or biallelic loss of the TP53 gene, which
encodes the tumor suppressor p53, a multifunctional transcription factor important for cellular response to DNA
damage, including cell cycle arrest and apoptosis.3 Most
patients with del(17p) also have a mutation of the other
TP53 allele and therefore lack wild-type TP53, leading to
genomic instability and reduced responsiveness to cytotoxic chemotherapy.2 The incidence of del(17p) is approximately 5-8% of patients with CLL at diagnosis and
increases with each relapse.4,5
Novel targeted therapies are therefore the preferred
treatment modality for previously untreated patients
whose disease bears the del(17p) mutation.6,7 Several new
agents are approved by the US Food and Drug
Administration and European Medicines Agency (EMA)
for adult patients with CLL/SLL regardless of del(17p) status, including the BTK inhibitors ibrutinib and acalabrutinib. In the RESONATE study of ibrutinib versus ofatumumab in patients with relapsed or refractory (R/R)
CLL/SLL,8 89% of ibrutinib-treated patients with del(17p)
achieved an objective response with long term follow-up.9
Similar results were observed in the single-arm RESONATE-17 study in R/R CLL10 in which 83% of patients
achieved an objective response; the 24-month progression-free survival (PFS) was 63%. Acalabrutinib, a secondgeneration BTK inhibitor, has been approved recently for
treatment-naïve (TN) patients with CLL/SLL regardless of
del(17p) status based on results from the ELEVATE TN
study.11,12 Notably, of the patients with del(17p) in that
study, only 16 were assigned to the single-agent acalabrutinib arm.
Other small molecule inhibitors approved in patients
with CLL/SLL and del(17p) include the BCL-2 inhibitor
venetoclax13 and the phosphatidylinositide-3-kinase
(PI3K)-δ inhibitor idelalisib.14 Stilgenbauer and colleagues
reported the results of venetoclax treatment in 158 mostly
R/R del(17p) patients,15 including a 77% overall response
rate (ORR) and an estimated 24-month PFS of 50%.
Notably, only five patients in this study were TN. In the
CLL14 trial which compared venetoclax and obinutuzumab to chlorambucil and obinutuzumab in TN CLL, 17
patients assigned to the venetoclax arm had del(17p).16
Similarly, studies supporting the approval of idelalisib
together with rituximab in the frontline setting by the
EMA included few TN CLL/SLL patients with del(17p).17,18
Collectively, only limited data are available for novel targeted therapies for previously untreated patients with
del(17p) CLL/SLL, and no large multi-center studies have
systematically examined this specific population.
Zanubrutinib (BGB-3111) is a next-generation BTK
inhibitor with favorable oral bioavailability and high
specificity for BTK, exhibiting comparatively lower offtarget activity than ibrutinib for structurally related kinashaematologica | 2021; 106(9)

es such as epidermal growth factor receptor (EGFR), interleukin-2 inducible kinase (ITK), and Src family kinases.19
The safety, pharmacokinetics, pharmacodynamics, and
preliminary activity of zanubrutinib were investigated in a
phase I/II study of patients with multiple B-cell malignancies in which high level, sustained BTK occupancy was
noted in both peripheral blood and lymph nodes at the
recommended phase II dose of 160 mg twice daily (bid).20
Encouraging activity was observed in a cohort of 78
patients with both TN and R/R CLL/SLL, including in a
subset of 16 patients with del(17p) or TP53 mutation who
achieved a 100% ORR.20 Activity of zanubrutinib was also
observed in a separate phase II trial of 91 R/R CLL/SLL
patients in China, including in a subset of 17 patients with
del(17p) who achieved a 88.2% ORR.21 Zanubrutinib has
recently received accelerated approval in the United States
for adult patients with mantle cell lymphoma who have
received at least one prior therapy22 and is currently undergoing further clinical testing in several prospective, multicenter, randomized phase III trials in CLL/SLL.
The SEQUOIA trial (clinicaltrialsgov. Identifier:
NCT03336333) is an open-label, multi center, randomized
phase III study of TN patients with CLL/SLL. Patients
without centrally confirmed del(17p) were randomized to
receive either zanubrutinib 160 mg bid until unacceptable
toxicity or disease progression (PD), or six cycles of rituximab and bendamustine. Considering the poor outcomes
associated with any standard chemoimmunotherapy regimen in patients with del(17p), those with centrally confirmed del(17p) during screening for SEQUOIA were not
randomized but assigned to single-agent zanubrutinib in a
separate cohort (Arm C). This is the first report of the safety and efficacy results in this high-risk del(17p) patient
cohort.

Methods
Study design and population
Eligible patients had confirmed CLL/SLL requiring treatment
per International Workshop on Chronic Lymphocytic Leukemia
(iwCLL) definition.23 TN adults were eligible if either aged
≥65 years or unsuitable for treatment with fludarabine, cyclophosphamide, and rituximab (FCR) and an Eastern Cooperative
Oncology Group (ECOG) performance status ≤2.24 Centrally confirmed del(17p) by fluorescence in situ hybridization with >7%
aberrant nuclei present was required. Patients had adequate endorgan function, including absolute neutrophil count (ANC)
≥1,000/mm3 and platelet count ≥75,000/mm3. For patients with
bone marrow involvement, ANC ≥750/mm3 and platelet count
≥50,000/mm3 were allowed. Patients with history of atrial fibrillation and/or long-term anticoagulation, or those requiring moderate or strong CYP3A inhibitors, could enroll.25 All Arm C patients
were assigned to receive zanubrutinib (160 mg bid) until intolerance or PD.
This study was conducted according to principles of the
Declaration of Helsinki and the International Conference on
Harmonization guidelines for Good Clinical Practice and
approved by the Institutional Review Board/Ethics Committee at
each participating site. All patients provided written informed
consent. This study adhered to CONSORT-10 guidelines for
reporting.26

Objectives and assessments
Key objectives for Arm C included assessments of ORR, PFS,
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duration of response (DOR), and safety (frequency and severity of
all treatment-emergent adverse events [AE]). ORR was assessed
per modified iwCLL criteria for CLL23,27 and per Lugano criteria for
SLL.28 Measurable disease, defined as ≥1 lymph node >1.5 cm in
the longest diameter and measurable in two perpendicular diameters, was assessed by computed tomography/magnetic resonance
imaging. Response assessments were performed every 12 weeks
after the first dose day for 96 weeks, then every 24 weeks until PD
or initiation of new, nonprotocol therapy, whichever came first.
Patients underwent bone marrow examination at baseline and for
confirmation of complete response (CR), or CR with incomplete
hematologic recovery (CRi), or if PD was suspected due to cytopenia.
All treatment-emergent AE, including AE of interest (AEI) based
on the known toxicity profile for BTK inhibitors occurring on or
after day 1 until 30 days after treatment discontinuation were
summarized. AEI were categorized in accordance with predefined
MedDRA search criteria (Online Supplementary Table S1). AE severity was assessed using the National Cancer Institute Common
Terminology Criteria for Adverse Events v4.03 and the Grading
Scale for Hematologic Toxicity in CLL Studies.23 Biomarkers were
assessed at baseline and optionally at progression.

Statistical analyses
Primary efficacy and safety analyses included all patients with
centrally confirmed del(17p) CLL/SLL receiving ≥1 dose of
zanubrutinib. ORR was summarized as percentage of responders
(CR, CRi, nodular partial response [nPR], partial response [PR], or
PR with lymphocytosis [PR-L]) with corresponding 95%
Confidence Interval (CI). An evaluation of ORR in subgroups
defined by key demographic and baseline disease characteristics
was conducted and summarized in a forest plot. DOR was defined
as time from first response until PD or death due to any cause. PFS
was measured from time of first dose to PD or death due to any
cause. Median DOR, PFS, and event-free survival rates were estimated using Kaplan-Meier methodology with corresponding
95% CI.

Results
Patient characteristics and disposition
Between February 3, 2018 and February 20, 2019, 109
patients with centrally confirmed del(17p) CLL/SLL were
enrolled from 59 sites in 13 countries (Online
Supplementary Table S2) and received ≥1 dose of zanubrutinib. Two additional patients without del(17p) were
assigned in error to this study arm and are not included in
the analysis. At the data cutoff date of April 15, 2020, the
median duration of study follow-up was 18.2 months
(range, 5.0–26.3). Median age at study entry was
70.0 years (range, 42–86); the majority of patients presented with CLL (90.8%). Reported reasons for treatment per
iwCLL criteria in order of frequency included progressive
marrow failure (41.3%); massive, progressive, or symptomatic lymphadenopathy (41.3%); significant fatigue
(33.0%); night sweats (32.1%); progressive lymphocytosis
with increase of > 50% over 2 months or doubling time of
<6 months (28.4%); massive, progressive, or symptomatic
splenomegaly (23.9%); and unintentional weight loss
(14.7%). More than one reason for treatment may have
been given, with a median of two reasons given for each
patient. Many patients had other high-risk disease characteristics, including 40 patients with CLL who presented as
Binet stage C (40.4%), 42 patients with bulky disease ≥5
2356

cm
(38.5%),
78
patients
with
elevated
β2-microglobulin (78.8% of 99 patients with available
data), and 67 patients with an unmutated immunoglobulin heavy chain variable (IGHV) locus (65.0% of 103
patients with sufficient RNA for testing). Furthermore, 32
(37.2%) of 86 patients with sufficient metaphases available for analysis had at least three distinct karyotypic
abnormalities defined as complex karyotype (Table 1).

Efficacy
The ORR was 94.5%, which included three patients
(2.8%) with CR, one patient (0.9%) with CRi, 95 (87.2%)
with PR, and four (3.7%) with PR-L (Table 2). Five (4.6%)
patients had a best response of stable disease (SD). One
patient (0.9%) had PD at the first response assessment.
Five (4.6%) patients met clinical CR criteria but did not
undergo bone marrow biopsy. Ninety-seven patients
(89.0%) remained on treatment at the time of analysis.
Nine patients with an initial response (8.3%) progressed
on study, four of whom had histologically confirmed
Richter transformation. Median time to transformation
was 13.7 months (time to transformation for each patient:
3.9, 13.6, 13.8, and 15.7 months). Two other patients had
new lesions seen on CT with positron emission tomography (PET) avidity for which biopsy could not definitively
confirm transformation, while one other patient had
accelerated CLL. Seven patients who have progressed
have discontinued treatment; two other patients with progression remained on treatment at time of data cutoff.
Four patients who progressed have died; two due to progression, one due to an adverse event after progression
(acute kidney injury), and one after progression due to
septic shock. Four patients (3.7%) discontinued treatment
due to AEs, of whom 2 have died (see Safety below),
while one patient discontinued treatment after withdrawal of consent and was lost to follow up.
Median PFS and OS were not reached. The estimated
18-month PFS rate was 88.6% (95% CI: 79.0–94.0) (Figure
1A), while the estimated 18-month OS rate was 95.1%
(95% CI: 88.4–98.0) (Figure 1B). The median time to
response was 2.8 months (range, 1.9–16.5) The median
DOR was not reached; 92.8% of patients had a DOR ≥ 12
months (Figure 1C). ORR was consistent across all prespecified demographic and baseline disease characteristics
(Figure 2).
Transient treatment-related lymphocytosis was
observed (Online Supplementary Figure S1A), but there was
a significant reduction in target lesion size by the first
scheduled response assessment, consistent with the short
median time to response (Online Supplementary Figure
S1A). The peak median change in absolute lymphocyte
count (ALC) and time to resolution of lymphocytosis both
appeared to be decreased from previous experience with
zanubrutinib.19 In an exploratory analysis, changes in ALC
were compared between patients with mutated and
unmutated IGHV locus. Patients with unmutated IGHV
showed a slight trend towards less treatment-related lymphocytosis (Online Supplementary Figure S1B), similar to
previous reports.9,29
Sixty-one patients (56.0%) began the study with at least
one cytopenia (Table 1), including 43 patients with anemia
(39.4%), eight patients with neutropenia (7.3%), and
28 patients with thrombocytopenia (25.7%) (Online
Supplementary Table S3). Eleven patients (10.1%) received
at least one dose of a granulocyte colony-stimulating fachaematologica | 2021; 106(9)
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tor, while one patient (0.9%) received at least one dose of
an erythrocyte-stimulating growth factor. Of those
patients with baseline anemia, 86.0% of patients demonstrated sustained improvement in hemoglobin; 75.0% of
patients with baseline neutropenia also demonstrated
sustained improvement in ANC, and 85.7% of patients

A

with baseline thrombocytopenia demonstrated sustained
improvement in platelet count (Online Supplementary
Table S3).
In an exploratory post hoc analysis, baseline characteristics and response rate were compared between patients
with a percentage of del(17p)-positive nuclei of ≥20%

Figure 1. Survival and
response analyses using the
Kaplan-Meier method. (A)
Progression-free survival as
determined by investigator
assessment. Shaded area
indicates 95% Confidence
Interval (CI). (B) Overall survival. Shaded area indicates
95% CI. (C) Duration of
response as determined by
investigator
assessment.
Shaded area indicates 95% CI.

B

C
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Table 1. Key patient and disease characteristics.

Table 2. Summary of investigator-assessed efficacy.

TN del(17p) CLL/SLL
(n=109)
Follow-up, median (range), mo
Demographics
Age, median (range), years
Male sex, n (%)
ECOG PS of 2, n (%)
Months since diagnosis, median (Q1 - Q3)
Disease characteristics
SLL, n (%)
Binet stage C for patients with CLL, n (%)
ALC (x 109/L), median
Hemoglobin (g/L), median
Platelet count (x 109/L), median
β2-microglobulina > 3.5 g/dL, n (%)
IGHV mutational status,b n (%)
Mutated
Unmutated
Bulky disease,c n (%)
Any TL LDi ≥ 5 cm
Any TL LDi ≥ 10 cm
Cytopenia present,d n (%)
Proportion of cells with del(17p), n (%)
7.5% – 10%
10.5% – 20.0%
20.5% – 50.0%
50.5% – 100%
Mean % (SD)
Karyotype status,e n (%)
Non-Complex (0 to 2 abnormalities)
Complex
3 or more abnormalities
5 or more abnormalities

18.2 (5.0-26.3)
70.0 (42-86)
78 (71.6)
14 (12.8)
21.6 (7.7-54.8)
10 (9.2)
40/99 (40.4)
65.1
120.0
154.0
78/99 (78.8)
36/103 (35.0)
67/103 (65.0)
42 (38.5)
11 (10.1)
61 (56.0)
16 (14.7)
44 (40.4)
13 (11.9)
36 (33.0)
36.0 (31.6)
54/86 (62.8)
32/86 (37.2)
23/86 (26.7)

AE: adverse event; ALC: absolute lymphocyte count; CLL: chronic lymphocytic
leukemia; ECOG PS: Eastern Cooperative Oncology Group performance status; IGHV:
immunoglobulin heavy chain variable; LDi: longest diameter; SD: standard deviation;
SLL: small lymphocytic lymphoma; TL: target lesion; TN: treatment-naïve; mo: months.
a
Ten patients had missing data. bSix patients had RNA quantity/quality not sufficient
for polymerase chain reaction (PCR) amplification of heavy-chain variable (VH)
region for sequencing. cPatients with any target lesion with longest diameter presented. dPatients having anemia (≤110 g/L), thrombocytopenia (≤ 100x109/L), or neutropenia (≤ 1.5 x 109/L). e23 patients had insufficient metaphases available for analysis.

[del(17p) high] versus patients with a percentage of >7% to
<20% [del(17p) low] (Online Supplementary Table S4).
Patients in the del(17p) high category were observed to
have a higher rate of unmutated IGHV (75% vs. 56.4% of
patients with a resulted test; P=0.0478) and complex karyotype status (56.8% vs. 22.4% of patients with sufficient
metaphases for analysis; P=0.0011); no other differences
in baseline characteristics were observed. Best ORR and
estimated 18-month PFS were 98% and 89%, respectively,
in the del(17p) high category and 92% and 88%, respectively, in the del(17p) low category.

Safety
AE of any grade reported in ≥10% of patients included
contusion (20.2%), upper respiratory tract infection
(19.3%), neutropenia/neutrophil count decreased (17.4%),
diarrhea (16.5%), nausea (14.7%), rash (13.8%), constipation (13.8%), back pain (12.8%), cough (11.9%), arthralgia
(11.0%), and fatigue (10.1%) (Table 3). Grade ≥3 events
were reported in 53 patients (48.6%), with
neutropenia/decreased neutrophil count (12.9%) and
pneumonia (3.7%) being the most common. Serious AE
2358

Efficacy Variable

TN del(17p) CLL/SLL
(n = 109)

Best response, n (%)
ORR (CR, PR, or PR-L), n (%) [95% CI]a
CR
CRi
PR
PR-L
SD
PD
Time to response, mo
PR-L or higher, median (range)
PR or higher, median (range)
DOR
Response ≥ 12 mo, % [95% CI]a
Estimated PFS rate, %
12 months [95% CI]a
18 months [95% CI]a

103 (94.5) [88-98]
3 (2.8)
1 (0.9)
95 (87.2)
4 (3.7)
5 (4.6)
1 (0.9)
2.79 (1.9-16.5)
2.89 (1.9-16.5)
92.8 [85.4-96.5]
94.5 [88.2-97.5]
88.6 [79.0-94.0]

CI: Confidence Interval; CLL: chronic lymphocytic leukemia; CR: complete response;
DOR: duration of response; ORR: overall response rate; PD: progressive disease; PFS:
progression-free survival; PR: partial response; PR-L: PR with lymphocytosis; SD: stable
disease; SLL: small lymphocytic lymphoma; TN: treatment-naïve. aTwo-sided ClopperPearson 95% CI.

(SAE) were reported in 36.7% of patients, with pneumonia (3.7%) being the most common. AE led to dose reduction in 6 (5.5%) patients and included thrombocytopenia,
diarrhea, gastritis, blood bilirubin increased, arthralgia,
myalgia, and headache. All six patients remain on treatment.
Four patients discontinued treatment due to AE; a 77year-old male patient had grade 4 pseudomonal sepsis
associated with grade 4 neutropenia and atrial fibrillation
who recovered, while another 72-year-old male patient
had grade 3 melanoma requiring surgery and adjuvant
therapy. One grade 5 event was reported in a 84-year-old
female patient with health-care associated pneumonia
diagnosed 8 days after the last dose of zanubrutinib which
was held for an unrelated procedure. This case was complicated by the development of sepsis which was assessed
as related to zanubrutinib. Finally, one grade 5 event was
reported in a 72-year-old male patient who developed disease progression at the week 36 response assessment
including massive enlargement of intra-abdominal lymph
nodes associated with hypercalcemia. Prior to discontinuation of study drug, the patient shortly thereafter had
renal failure requiring dialysis and subsequently died due
to pulmonary edema. No sudden or unknown deaths
were reported.
AEI known to be associated with BTK inhibitors were
characterized in greater detail, including grouping of similar AE by category (Online Supplementary Table S1). AEI
reported in ≥10% of treated patients included infections
(64.2%; 13.8% grade ≥3), minor bleeding (26.6%), bruising (24.8%; 0% grade ≥3), neutropenia (18.3%; 13.8%
grade ≥3), diarrhea (15.6%; 0.9% grade ≥3), nausea
(13.8%; 0% grade ≥3), arthralgia (11.0%; 0% grade ≥3),
fatigue (10.1%; 0.9% grade ≥3) (Online Supplementary Table
S5). The most common infections reported in ≥ 5% of
patients included upper respiratory tract infection
(19.3%), pneumonia (8.3%), nasopharyngitis (7.3%), and
urinary tract infection (6.4%); most of these were grade 1
or 2 events. Prophylaxis against opportunistic infections
was allowed per local standard of care but not required;
haematologica | 2021; 106(9)
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Figure 2. Subgroup analysis of overall response rate. Overall response rate presented as of November 1, 2019. Two-sided Clopper-Pearson 95% Confidence Interval
(CI) are used. CLL: chronic lymphocytic lymphoma; ECOG PS: Eastern Cooperative Oncology Group performance status; LDH: lactate dehydrogenase; LDi: longest
diameter; SLL: small lymphocytic leukemia. aPatients with any target lesion with longest diameter presented. bSix patients had RNA quantity/quality not sufficient for
polymerase chain reaction amplification of immunoglobulin heavy chain variable (VH) region for sequencing. cPatients having anemia (≤110 g/L), thrombocytopenia
(≤100x109/L), or neutropenia (≤1.5x109/L). d10 patients had missing data. e23 patients had insufficient metaphases available for analysis.

no opportunistic infections were reported.
Of other malignancies reported on study, most were
dermatological malignancies reported in ten patients
(9.2%). Other than two patients with melanoma, all were
basal and squamous cell carcinomas of the skin (grade 1/2)
reported from patients in Australia and New Zealand,
where skin cancers are frequent, especially in patients
with CLL/SLL.30,31 One patient developed grade 3
melanoma requiring surgery and adjuvant therapy with
pembrolizumab leading to discontinuation of zanubrutinib. Five patients (4.6%) reported a non-dermatologic
other malignancy. One patient developed localized breast
cancer for which axillary lymph node biopsy indicated
disease transformation to DLBCL, while one other patient
developed lung cancer for which interlobar lymph node
biopsy also indicated disease transformation to DLBCL.
Three patients reported a transitional cell carcinoma of the
bladder or ureter, all of whom underwent resection withhaematologica | 2021; 106(9)

out known residual disease and remain on study drug
treatment.
The usage of therapeutic anticoagulation was not
restricted on this study; 20 patients (18.3%) were reported
to have taken a therapeutic anticoagulant including warfarin, direct-acting oral anticoagulants, and heparins during the study, while 27 patients (24.8%) were reported to
have taken an oral platelet aggregation inhibitor, including
aspirin, during the study. Bleeding of any type was reported in 47.7% of patients (4.6% grade ≥3). Major bleeding
events were defined as any bleeding event with grade ≥3,
any SAE, or any bleed affecting the central nervous system
(CNS); these occurred in six patients (5.4%). A description
of each event, including any confounding factors, is presented in Online Supplementary Table S6; in two patients,
bleeding occurred in the setting of a surgical procedure
without dose hold as advised per protocol. All patients
continued study treatment after dose interruption. No
2359
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Table 3. Most common adverse events regardless of causality. Adverse events of any grade occurring in ≥ 5% of patients and all grade ≥3 adverse
events occurring in ≥2% of patients are shown.a

Term

Any Grade

Grade 1/2

Grade 3
n (%)

Grade 4

Grade 5

Patients with at least one AE
Hematologic AE
Neutropenia
Neutrophil count decreased
Nonhematologic AE
Contusion
Upper respiratory tract infection
Diarrhea
Nausea
Constipation
Rash
Back pain
Cough
Arthralgia
Fatigue
Dyspepsia
Headache
Fall
Pain in extremity
Pneumonia
Abdominal pain
Dyspnea
Epistaxis
Hematuria
Nasopharyngitis
Pruritus
Pyrexia
Hypertension
Muscle spasms
Urinary tract infection
Vomiting
Hematoma
Musculoskeletal pain
Skin laceration

106 (97.2)

53 (48.6)

44 (40.4)

7 (6.4)

2 (1.8)

13 (11.9)
6 (5.5)

3 (2.8)
2 (1.8)

7 (6.4)
1 (0.9)

3 (2.8)
3 (2.8)

0 (0)
0 (0)

22 (20.2)
21 (19.3)
18 (16.5)
16 (14.7)
15 (13.8)
15 (13.8)
14 (12.8)
13 (11.9)
12 (11.0)
11 (10.1)
10 (9.2)
9 (8.3)
9 (8.3)
9 (8.3)
9 (8.3)
8 (7.3)
8 (7.3)
8 (7.3)
8 (7.3)
8 (7.3)
8 (7.3)
8 (7.3)
7 (6.4)
7 (6.4)
7 (6.4)
7 (6.4)
6 (5.5)
6 (5.5)
6 (5.5)

22 (20.1)
21 (19.3)
17 (15.6)
16 (14.7)
15 (13.8)
15 (13.8)
13 (11.9)
13 (11.9)
12 (11.0)
10 (9.2)
10 (9.2)
8 (7.3)
7 (6.4)
8 (7.3)
5 (4.6)
8 (7.3)
8 (7.3)
7 (6.4)
6 (5.5)
8 (7.3)
8 (7.3)
7 (6.4)
5 (4.6)
7 (6.4)
5 (4.6)
7 (6.4)
6 (5.5)
5 (4.6)
6 (5.5)

0 (0)
0 (0)
1 (0.9)
0 (0)
0 (0)
0 (0)
1 (0.9)
0 (0)
0 (0)
1 (0.9)
0 (0)
1 (0.9)
2 (1.8)
1 (0.9)
3 (2.8)
0 (0)
0 (0)
1 (0.9)
2 (1.8)
0 (0)
0 (0)
1 (0.9)
2 (1.8)
0 (0)
2 (1.8)
0 (0)
0 (0)
1 (0.9)
0 (0)

0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)

0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
1 (0.9)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)

AE: adverse event. aData are for treatment-emergent adverse events in the 109 patients in this arm of the study.

bleeding events affecting the CNS were reported.
A history of atrial fibrillation or flutter was reported in
seven patients (6.4%); four patients (3.7%) entered the
study with controlled and hemodynamically stable atrial
fibrillation or flutter. An AE of atrial fibrillation or flutter
was reported in three patients (2.8%). One grade 2 event
was reported in a 71-year-old male patient with hypertension and prior history of atrial fibrillation, while a grade 3
event was reported in a 78-year-old male patient who was
septic from cholecystitis. Both of these events resolved
and did not require discontinuation of study treatment.
Finally, one grade 4 event was reported in a 77-year-old
male patient with grade 3 hypertension at baseline, who
discontinued treatment due to sepsis secondary to
Pseudomonas; atrial fibrillation resolved following recovery from sepsis.

Discussion
In this report, we have shown the activity and safety of
zanubrutinib in a large non-randomized cohort of treatment-naïve CLL/SLL patients with centrally confirmed
del(17p), enrolled as part of the global SEQUOIA trial. As
expected, these results compare favorably with those
2360

from previous studies of TN patients treated with
chemoimmunotherapy, including the CLL8 trial of
FCR.1,2,32 At the present time, prospective clinical trial data
from BTK inhibitor-treated patients with TN del(17p)
CLL/SLL are limited. Patients with del(17p) were not eligible for enrollment in RESONATE-233 and the ECOGE191234 trials evaluating ibrutinib in the TN setting. The
Alliance A041702 study, comparing chemotherapy, ibrutinib, or ibrutinib and rituximab in older patients with TN
CLL/SLL, did allow patients with del(17p) to enroll; of
these, 6% had del(17p), and only nine patients were
assigned to receive ibrutinib alone.35 Two studies examining combinations of novel targeted therapies with antiCD20 antibodies also enrolled a small number of TN
patients with del(17p), including the iLLUMINATE study,
where 14 patients with del(17p) received combination
ibrutinib and obinutuzumab.36 In a single-center, phase 2
study, single-agent ibrutinib was evaluated in 35 patients
with TN CLL; notably, this population was selected based
on cytogenetics or TP53 sequencing and allowed younger
and/or fit patients, leading to enrollment of a population
with a median age of 62.37,38 At a median follow-up time
of 15 months, ORR was reported as 97%, including 12%
CR, 70% PR, and 15% PR-L.
The ORR with zanubrutinib observed in the present
haematologica | 2021; 106(9)
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study appears at least comparable with the reported ibrutinib experience. Median time to response essentially was
defined by the first scheduled response assessment (Figure
1C), consistent with reduction in target lesion size (Online
Supplementary Figure S1A) and resolution of cytopenias
(Online Supplementary Table S3). Consistent with previous
studies of other BTK inhibitors,12,32,37 CR were uncommon
with short follow-up; longer follow-up will be needed to
more precisely define the CR rate. Response rates appear
to be similarly high regardless of coincident risk factors,
including IGHV mutational status and complex karyotype
status, though the low number of non-responders may
limit the ability to detect meaningful differences between
subgroups.
In the UK LRF CLL4 trial, del(17p) in >20% of nuclei
was found to be independently associated with shorter
PFS in patients treated with chemoimmunotherapy.39,40 As
expected, patients with a higher burden of del(17p) were
associated with a higher rate of poor prognostic factors
such as unmutated IGHV status and complex karyotype.
When examining ORR and progression events in the current study, ORR appeared to be similar in patients without
and with del(17p) in ≥20% of nuclei (Online Supplementary
Table S4), suggesting that zanubrutinib has preserved
activity in high-risk patients with enrichment of malignant cells for del(17p). This is comparable to the activity
seen in the RESONATE-17 trial of R/R patients with
del(17p) treated with ibrutinib.10
Ten patients progressed on study. In addition to presence of del(17p), seven patients who progressed had an
unmutated IGHV locus. Karyotype analysis was available
for eight patients who had progressed, of whom two had
complex karyotype (number of abnormalities: 5 and 6).
Four patients had histologically confirmed transformation
to aggressive lymphoma, while two patients had suspected transformation. The present results compare favorably
to those reported with chemoimmunotherapy, where
23% of patients with del(17p) treated in the first line experienced disease transformation, with a median time to
transformation of 12 months.41 In the RESONATE-17 trial
of R/R CLL patients, 44% of progression events were due
to transformation, most within the first 6 months of treatment.10 Similarly, both early progression events in the TN
del(17p) or TP53 populations treated with ibrutinib, as
reported by Farooqi and colleagues, occurred due to
Richter transformation.37 These data are in line with the
known association of del(17p) and transformation to
aggressive lymphomas.42 Long term outcomes for patients
with del(17p) treated with ibrutinib were reported by Ahn
and colleagues,38 showing an approximate 5-year PFS of
75%. Further follow-up will be required to demonstrate
the durability of responses to zanubrutinib. Additional
analyses, including correlation of response and progression with concurrent genomic abnormalities and other
genetic mutations (e.g., TP53, NOTCH1, BTK, and PLCG2
mutations), both at baseline and at the time of progression, are currently in progress.
The clinically meaningful activity noted in this patient
series appears to be associated with a favorable toxicity
profile and is consistent with that reported in other studies
of zanubrutinib to date.20,43 Despite enrolling a more elderly and comorbid population and allowing for therapeutic anticoagulation on study, the incidence of grade ≥3 AE
or SAE leading to major bleeding was 5.6% with no CNS
events reported, and all patients able to continue study
haematologica | 2021; 106(9)

drug after dose interruption. Consistent with its greater
selectivity for BTK and less inhibition of kinases such as
EGFR, Src, and others, the incidence of grade 3 AE such as
diarrhea, arthralgia, and myalgia were all ≤1%.
Importantly, only three patients on this study reported
treatment-emergent atrial fibrillation, six patients required
ongoing dose reduction, and four patients discontinued
zanubrutinib due to an AE. Two phase III randomized
studies in patients with R/R CLL/SLL44 and Waldenström
macroglobulinemia45 are ongoing to directly compare the
efficacy and safety profiles of ibrutinib and zanubrutinib.
Limitations of this study include the relatively short
duration of follow-up and its single-arm design. A retrospective analysis for baseline TP53 mutations is currently
being performed for this study arm and the larger randomized arms. Analogous to other BTK inhibitors, the singleagent activity of zanubrutinib is not expected to induce a
deep response with eradication of minimal residual disease (MRD). Several studies have recently reported
achievement of undetectable MRD in patients with TN
CLL/SLL, including those patients with del(17p), by combining a BTK inhibitor with obinutuzumab or venetoclax.36,46,47 The SEQUOIA trial is currently enrolling
patients in Arm D, which will evaluate the safety and
activity of a combination of zanubrutinib with venetoclax
in TN CLL/SLL patients with del(17p). In summary, these
results indicate that single-agent zanubrutinib is active and
generally well tolerated in this very high-risk population.
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